Rare Diseases


Apremilast Reduces Oral Ulcers in Behçet’s Syndrome

January 28, 2020

Apremilast (Otezla, Celgene) resulted in a greater reduction in the number of oral ulcers associated with Behçet’s syndrome than placebo, say researchers recently writing in the New England Journal of Medicine.

New Treatment Option for Behçet’s Disease

July 22, 2019

On Friday, the U.S. Food and Drug  Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.

Abatacept Boosts Chances of Remission in Relapsing Granulomatosis

December 24, 2013

A small multicenter study shows that intravenous abatacept (Orencia) can produce a high rate of remission in patients with in non-severe relapsing Wegener’s granulomatosis with polyangiitis (GPA).

Options in Tough-To-Treat Uveitis

October 29, 2013

Reports in a pediatric ophthalmology journal reveal risk factors and best treatments for refractory/recurrent uveitis in JIA.

Granulomatosis With Polyangiitis, With Atypical Features

June 20, 2013

The manifestations of granulomatosis with polyangiitis varies widely. This case study describes a 49-year-old man who presented with cough, chills, and chest pain who had a mediastinal mass and ocular involvement.

Babesiosis in a Patient With Corticosteroid-Resistant Uveitis

August 30, 2012

The tumor necrosis factor α antagonist infliximab has been used for treating patients with uveitis resistant to corticosteroids.

Behçet syndrome: Taking a systemic approach

August 30, 2009

Behçet syndrome is a multisystem disease characterized by variable clinical manifestations. The diagnosis is based on recognition of a group of clinical features.